phosphorylcholine has been researched along with Ovarian Neoplasms in 12 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer." | 9.16 | Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. ( Atkinson, E; Bast, RC; Coleman, RL; Coombes, KR; Dice, K; Dyer, M; Fu, S; Gershenson, DM; Hennessy, BT; Howard, A; Jackson, E; Ju, Z; Kavanagh, JJ; Kundra, V; Kurzrock, R; Levenback, CF; Li, J; Li, Y; Markman, M; Mills, GB; Ng, CS; Sood, AK; Stemke-Hale, K; Wolf, JK, 2012) |
| "On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer." | 5.16 | Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. ( Atkinson, E; Bast, RC; Coleman, RL; Coombes, KR; Dice, K; Dyer, M; Fu, S; Gershenson, DM; Hennessy, BT; Howard, A; Jackson, E; Ju, Z; Kavanagh, JJ; Kundra, V; Kurzrock, R; Levenback, CF; Li, J; Li, Y; Markman, M; Mills, GB; Ng, CS; Sood, AK; Stemke-Hale, K; Wolf, JK, 2012) |
| " When administered to human ovarian tumor-bearing mice using a recurring dosing regimen comparable to that used clinically, polyMPC-Dox significantly retarded tumor growth relative to treatment with free Dox." | 1.43 | Evaluation of PolyMPC-Dox Prodrugs in a Human Ovarian Tumor Model. ( Arenas, RB; Crisi, GM; Emrick, T; McRae Page, S; Mora, MC; Schneider, SS; Skinner, M; Wong, KE, 2016) |
| "Treatment with perifosine concurrently with cisplatin significantly enhanced the antitumor effect of cisplatin." | 1.42 | Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary. ( Hashimoto, K; Hisamatsu, T; Isobe, A; Kawano, M; Kimura, T; Kuroda, H; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, R; Testa, JR, 2015) |
| "We recently showed that epithelial ovarian cancer (EOC) possesses an altered MRS-choline profile, characterised by increased phosphocholine (PCho) content to which mainly contribute over-expression and activation of choline kinase-alpha (ChoK-alpha)." | 1.40 | Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. ( Bagnoli, M; Canevari, S; De Cecco, L; Granata, A; Iorio, E; Mezzanzanica, D; Nicoletti, R; Pisanu, ME; Podo, F; Ricci, A; Tinaglia, V, 2014) |
| "Perifosine-response was associated with the expression (FDR<0." | 1.39 | Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest. ( Abbasi, F; Al Sawah, E; Apte, SM; Bou Zgheib, N; Chen, X; Chon, HS; Judson, PL; Lancaster, JM; Marchion, DC; Ramirez, IJ; Wenham, RM; Xiong, Y, 2013) |
| "Endometrial and ovarian cancer cells were treated with various concentrations of ErPC, and its effect on cell growth, cell cycle, apoptosis, and related measurements was investigated." | 1.35 | Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells. ( Narahara, H; Nasu, K; Takai, N; Ueda, T, 2008) |
| "In contrast to malignant ovarian cancer cells, immortalized human ovarian epithelial cells did not respond to any of these lipids to increase the secretion of IL-8, although these cells secreted similar basal levels of IL-8 (310 pg/ml/10,000 cells)." | 1.31 | Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. ( Baudhuin, LM; Hong, G; Mok, SC; Morrison, BH; Schwartz, BM; Wu, W; Xiao, YJ; Xu, Y, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z | 1 |
| Tan, Y | 1 |
| Li, X | 1 |
| Quan, J | 1 |
| Bode, AM | 1 |
| Cao, Y | 1 |
| Luo, X | 1 |
| Al Sawah, E | 1 |
| Chen, X | 1 |
| Marchion, DC | 1 |
| Xiong, Y | 1 |
| Ramirez, IJ | 1 |
| Abbasi, F | 1 |
| Bou Zgheib, N | 1 |
| Chon, HS | 1 |
| Wenham, RM | 1 |
| Apte, SM | 1 |
| Judson, PL | 1 |
| Lancaster, JM | 1 |
| Granata, A | 1 |
| Nicoletti, R | 1 |
| Tinaglia, V | 1 |
| De Cecco, L | 1 |
| Pisanu, ME | 1 |
| Ricci, A | 1 |
| Podo, F | 2 |
| Canevari, S | 2 |
| Iorio, E | 2 |
| Bagnoli, M | 1 |
| Mezzanzanica, D | 2 |
| Sasano, T | 1 |
| Mabuchi, S | 1 |
| Kuroda, H | 1 |
| Kawano, M | 1 |
| Matsumoto, Y | 1 |
| Takahashi, R | 1 |
| Hisamatsu, T | 1 |
| Sawada, K | 1 |
| Hashimoto, K | 1 |
| Isobe, A | 1 |
| Testa, JR | 1 |
| Kimura, T | 1 |
| Wong, KE | 1 |
| Mora, MC | 1 |
| Skinner, M | 1 |
| McRae Page, S | 1 |
| Crisi, GM | 1 |
| Arenas, RB | 1 |
| Schneider, SS | 1 |
| Emrick, T | 1 |
| Takai, N | 1 |
| Ueda, T | 1 |
| Nasu, K | 1 |
| Narahara, H | 1 |
| Engel, JB | 1 |
| Schönhals, T | 1 |
| Häusler, S | 1 |
| Krockenberger, M | 1 |
| Schmidt, M | 1 |
| Horn, E | 1 |
| Köster, F | 1 |
| Dietl, J | 1 |
| Wischhusen, J | 1 |
| Honig, A | 1 |
| Sun, H | 1 |
| Yu, T | 1 |
| Li, J | 2 |
| Fu, S | 1 |
| Hennessy, BT | 1 |
| Ng, CS | 1 |
| Ju, Z | 1 |
| Coombes, KR | 1 |
| Wolf, JK | 1 |
| Sood, AK | 1 |
| Levenback, CF | 1 |
| Coleman, RL | 1 |
| Kavanagh, JJ | 1 |
| Gershenson, DM | 1 |
| Markman, M | 1 |
| Dice, K | 1 |
| Howard, A | 1 |
| Li, Y | 1 |
| Stemke-Hale, K | 1 |
| Dyer, M | 1 |
| Atkinson, E | 1 |
| Jackson, E | 1 |
| Kundra, V | 1 |
| Kurzrock, R | 1 |
| Bast, RC | 1 |
| Mills, GB | 1 |
| Alberti, P | 1 |
| Spadaro, F | 1 |
| Ramoni, C | 1 |
| D'Ascenzo, S | 1 |
| Millimaggi, D | 1 |
| Pavan, A | 1 |
| Dolo, V | 1 |
| Spruss, T | 1 |
| Bernhardt, G | 1 |
| Schönenberger, H | 1 |
| Engel, J | 1 |
| Schwartz, BM | 1 |
| Hong, G | 1 |
| Morrison, BH | 1 |
| Wu, W | 1 |
| Baudhuin, LM | 1 |
| Xiao, YJ | 1 |
| Mok, SC | 1 |
| Xu, Y | 1 |
1 trial available for phosphorylcholine and Ovarian Neoplasms
| Article | Year |
|---|---|
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Su | 2012 |
11 other studies available for phosphorylcholine and Ovarian Neoplasms
| Article | Year |
|---|---|
DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHKα to disrupt choline metabolism.
Topics: Carbonyl Reductase (NADPH); Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cho | 2022 |
Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Cisplatin; Hu | 2013 |
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chol | 2014 |
Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resist | 2015 |
Evaluation of PolyMPC-Dox Prodrugs in a Human Ovarian Tumor Model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Female; Humans; Maximum Tolerated Dos | 2016 |
Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells.
Topics: Apoptosis; Caspase 9; Cell Cycle; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Cycl | 2008 |
Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2011 |
Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Casp | 2011 |
Alterations of choline phospholipid metabolism in ovarian tumor progression.
Topics: Carbon Radioisotopes; Cell Line, Tumor; Choline; Choline Kinase; Disease Progression; Female; Humans | 2005 |
Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug | 1993 |
Lysophospholipids increase interleukin-8 expression in ovarian cancer cells.
Topics: Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Interleuki | 2001 |